Baden LR, El Sahly HM, Essink B, Karen Kotloff MD, Sharon Frey MD, Rick Novak MD, David Diemert MD, Stephen AS, Nadine R, Buddy C, John M, Shishir K, Nathan S, Joel S, Adam B, Carlos F, Howard S, Kathleen N, Lawrence C, Peter G, Holly J, Dean F, Mary M, John M, Laura P, Julie L, Barney S, Hamilton B, Rolando P, Conor K, Brett L, Weiping D, Honghong Z, Shu H, Melanie I, Jacqueline M, and Tal Z, COVE Study Group (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 384:403-416.
Crossref

Del RC, Collins LF, Malani P (2020). Long-term health consequences of COVID-19. JAMA. WHO.
Crossref

Eyre DW, Lumley SF, Wei J, Jia W, Stuart C, Tim J, Anita J, Gerald J, DeniseO'D, Alison H, Stephanie BH, Brian DM, Yvonne J, David IS, Daniel E, Sarah H, Derrick WC, Tim EAP, Timothy M, Nicole ES, Philippa CM, Koen BP, Sarah W, Katie J (2021). Quantitative SARS-CoV-2 anti-spike responses to Pfizer BioNTech and Oxford AstraZeneca vaccines by previous infection status. Clinical Microbiology and Infection (10):1516.e7-1516.e14. [Epub ahead of print]
Crossref

Folegatti PM, Ewer KJ, Aley PK, Pedro MF, Katie JE, Parvinder KA, Brian A, Stephan B, Sandra BR, Duncan B, Sagida B, Mustapha B, Elizabeth AC, Christina D, Saul NF, Adam F, Amy LF, Bassam H, Paul H, Daniel J, Rajeka L, Rebecca M, Angela MM, Katrina MP, Maheshi R, Hannah R, Matthew S, Richard Tarrant, Merryn V, Catherine G, Alexander DD, Adrian VSH, Teresa L, Sarah CG, Andrew JP, Oxford COVID Vaccine Trial Group (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396:467-478.

Goldberg Y, Mandel M, Woodbridge Y, Ronen F, Ilya N, Rami Y, Arnona Z, Laurence F, Amit H (2021). Protection of previous SARS-COV-2 infection is similar to that of BNT162b2 vaccine protection: A three month nationwide experience from Israel. Preprint at medRxiv.
Crossref

Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF (2021). Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. New England Journal of Medicine 384(14):1372-1374.
Crossref

Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (2020). Corona virus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science 27(1):1-23.
Crossref

Medicines and Healthcare products Regulatory Agency (2020a). Regulatory Approval of Pfizer/BioNTech Vaccine for COVID-19 (GOV. UK, 2020).

View   

Medicines and Healthcare products Regulatory Agency (2020b). Oxford University/ AstraZeneca COVID-19 Vaccine Approved (GOV.UK, 2020);

View

Menni C, Klaser K, May A, Lorenzo P, Joan C, Panayiotis L, Carole HS, Long HN, David AD, Jordi M, Christina H, Somesh S, Michela A, Benjamin M, Liane SC, Erika M, Mark S, Marc M, Amit DJ, Massimo M, Alexander H, Anna LG, Andrew TC, Jonathan W, Claire JS, Ana MV, Sebastien O, Tim D (2021). Vaccine side effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infectious Diseases.
Crossref

Müller L, Andrée M, Moskorz W, Ingo D, Lara W, Ramona G, Johannes P, Jonas H, Anastasia R, Denise R, Philipp NO, Rebekka R, Sandra H, Andreas W, Christopher M, Ralf G, Jörg T, Ortwin A, Heiner S (2021). Age dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clinical Infectious Disease 73(11): 2065-2072. Available from:
Crossref

Parry H, Bruton R, Tut G, Myah A, Stephens C, Sian F, Huissoon A, Meade R, Kevin B, Gayatri A, Bassam H, Alex GR, Jianmin Z (2021). Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1. SSRN Electronic Journal 15 p. Available at:
Crossref

Pritchard E, Matthews PC, Stoesser N, David WE, Owen G, Karina-Doris V, Joel J, Thomas H, Harper V, Iain B, John IB, John NN, Jeremy F, Ian D, Emma R, Ruth S, Derrick C, Tim EAP, Sarah W, Koen BP (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine 27:1370-1378.
Crossref

Ramasamy MN, Minassian AM, Ewer KJ, Amy LF, Pedro M, Daniel RO, Merryn V, Parvinder KA, Brian A, Gavin B, Sandra Belij-R, Lisa B, Sagida B, Mustapha B, Katrina C, Harry C, Sue C, Paola C, Elizabeth AC, Rachel C-J, Christina D, Katherine RWE, Sofiya F, Michelle F, Diane G, Catherine G, Bassam H, Mimi MH, Daniel J, Carina CDJ, Elizabeth JK, Simon K, Alison ML, Alice L, May NL, Rebecca M, Natalie GM, Yama M, Alasdair PSM, Mihaela P, Emma P, Jade R, Thomas R, Sarah R, Hannah R, Adam JR, Amy LR-R, Stephen S, Nisha S, Catherine CS, Matthew DS, Rinn S, Richard T, Yrene T, Kelly MT, Tonya LV, Sarah CW, Marion EEW, Alexander DD, Adrian VSH, Teresa L, Sarah CG, Saul NF, Andrew JP, Oxford COVID Vaccine Trial Group (2021). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled phase 2/3 trial. Lancet 396:1979-93.

Rinott E, Youngster I, Lewis YE (2021). Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program - Israel, December 2020-February 2021. MMWR Morb Mortal Weekly Report 70:326-328.
Crossref

Singh AK, Phatak SR, Singh NK, Gupta A, Sharma A, Bhattacharjee K, Sing R (2021). Antibody Response after First-dose of ChAdOx1-nCOV (Covishield TM®) and BBV-152 (Covaxin TM®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study. medRxiv preprint; this version posted April 13, 2021.
Crossref

Wei J, Stoesser N, Matthews PC, Daniel A, Ruth S, Iain B, John IB, John NN, Jeremy F, Ian D, Emma R, Alison H, Brian DM, Sarah H, Yvonne JE, David IS, Derrick WC, Tim EAP, Koen BP, David WE, Sarah W, the COVID-19 Infection Survey team (2020). Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature microbiology.
Crossref

WHO corona virus disease (COVID-19) dashboard (2020). Available at:

View

World Health Organization (WHO) (2021). WHO Coronavirus Disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Available at:

View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062.
Crossref